Business Context and Reporting Period
This Form 8-K was filed by Obalon Therapeutics, Inc. on September 8, 2017, reporting events that occurred on September 6 and 7, 2017. The filing discloses the appointment of Kelly Huang as Chief Operating Officer (COO) and details the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
- Base Salary: $425,000 annually.
- Target Cash Bonus: 55% of annual base salary (prorated for fiscal 2017).
- Signing Bonus: $75,000 one-time cash payment.
- Equity Grant: Option to purchase 269,230 shares of common stock.
Material Changes
The primary material change is the addition of Kelly Huang to the executive team as COO, effective September 6, 2017. Mr. Huang brings prior experience as Vice President and General Manager at Galderma, Operating Partner at Spindletop Capital, and various executive roles at Intrexon, Endo Pharmaceuticals, and Johnson & Johnson.
Guidance, Outlook, and Compensation Details
The filing outlines specific terms of the employment and retention agreements:
- Equity Vesting: 25% of the stock option vests on the first anniversary; the remainder vests in monthly installments over 36 months. Vesting is contingent on continued employment and relocation to the San Diego area.
- Relocation Obligations: The signing bonus is subject to repayment if Mr. Huang resigns or is terminated for cause within one year, or if he fails to purchase a residence in San Diego within six months or relocate his primary residence within two years.
- Severance Protections:
- Standard Qualifying Termination: 12 months of base salary and up to 12 months of medical benefits.
- Change in Control Termination: 12 months of base salary, pro-rated target bonus, 100% acceleration of unvested equity, and up to 12 months of medical benefits.
- Agreement Duration: The Retention Agreement is effective for three years with automatic three-year renewals unless terminated by notice.
Investor Verification Checklist
- Verify the impact of the $425,000 base salary and potential bonus on the company's operating expenses for fiscal 2017 and beyond.
- Confirm the dilution impact of the 269,230 share option grant on existing shareholders.
- Review the specific definitions of "cause" and "good reason" in the employment agreement to understand severance triggers.
- Monitor the company's ability to meet the relocation conditions tied to the signing bonus repayment clause.